

**LIST OF CLINICAL TRIALS IN MARIA SKŁODOWSKA-CURIE NATIONAL RESEARCH INSTITUTE OF ONCOLOGY
KRAKOW BRANCH**

Department	Protocol number	Diagnosis	Name of Clinical Trial
Klinika Onkologii Klinicznej	MK-3475-564	Renal Cell Carcinoma	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Klinika Onkologii Klinicznej	MK-3475-522	Breast cancer	A Phase III, Randomized, Double-Blind, Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Klinika Onkologii Klinicznej	MK-3475-427	Renal Cell Carcinoma	A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) Clinical Trial
Klinika Onkologii Klinicznej	WO39210	Renal Cell Carcinoma	A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Klinika Onkologii Klinicznej	CA209 915	Melanoma	A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIB/b/d or Stage IV Melanoma
Klinika Onkologii Klinicznej	MK-3475-426	Renal Cell Carcinoma	A Phase III, Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment of Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)
Klinika Onkologii Klinicznej	CO39262 (TRYLOGIA)	Melanoma	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in previously untreated BRAFV600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma
Klinika Onkologii Klinicznej	CA 209 511	Melanoma	Phase IIIB/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
Klinika Onkologii Klinicznej	CA 209 214	Renal Cell Carcinoma	A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell

Klinika Onkologii Klinicznej	CA 209 238	Melanoma	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence
Klinika Onkologii Klinicznej	EGF 106 708 (ALTTO)	Breast cancer	A randomized, multi-center, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
Klinika Ginekologii Onkologicznej	YO39523	Reproductive cancer	A Phase III, Multicenter, Randomized, Study of Atezolimumab Versus Placebo Administrated in Combination with Paclitaxel, Carboplatin, and Bevacilizumab to Pateints with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer